Patients previously prescribed one epinephrine autoinjector device may be switched to an alternative device by their pharmacist or physician -sometimes without training on the new device. It is unclear whether "device switches" without retraining compromise the ability to deliver epinephrine.
Methods
We evaluated mothers of food-allergic children participating in a UK study of epinephrine auto-injectors (EAI), 1 year after they were first trained to use an EAI, either Anapen or Epipen (old design). Participants' ability to deliver epinephrine using their device was assessed using a simulated anaphylaxis scenario. Participants then underwent repeat assessment using a different EAI device, randomly allocated, without training on the new device. The UK-approved EAIs Epipen (new/old designs), JEXT or Anapen were used, or Intelliject, an EAI with audio/visual prompts approved in North America as AuviQ(tm) and Allerject TM . ISRCTN29175528
Results
We evaluated ability to deliver epinephrine in 108 participants. Overall success rates were similar using their original EAI 68/108 (63%) to the new device 65/108 (60%; P=0.775). However the outcome differed significantly for different types of device switch. Success rates were lower when switching between Anapen and either old Epipen, new Epipen or JEXT (6/18; 33%) compared with switching from old Epipen to either new Epipen or JEXT (30/42; 71%; P<0.009). Success rates were highest when switching from Anapen or old Epipen to Intelliject (26/28; 93%) compared with switching to other EAIs (39/80; 49%; P=0.000).
Conclusions
The safety of EAI device switches varies according to the specific device. Switches to Intelliject appear to be safer than other forms of device switch.
